Company Overview and News

 
Impact Minerals major shareholder builds stake through $2 million note conversion

2018-02-05 proactiveinvestors.com.au
Impact Minerals Limited (ASX:IPT) major shareholder, the Andrew Forrest related Squadron Resources Pty Ltd, continues to build its interest in the gold, silver and base metals explorer.

 
Buxton Resources calls time in share trading pending key news flow

2017-09-25 proactiveinvestors.com.au
Buxton Resources Ltd (ASX:BUX) is preparing to reveal exploration results, with the ASX granting the company a trading halt to prepare.

 
Buxton Resources secures funds for nickel, copper exploration

2017-05-15 proactiveinvestors.com.au
Buxton Resources (ASX:BUX) has successfully completed a bookbuild to raise up to $4 million from sophisticated and professional investors via the issue of shares at $0.23 each.

 
Buxton Resources gets ready to raise

2017-05-11 proactiveinvestors.com.au
Buxton Resources (ASX:BUX) has been granted a trading halt by the ASX, pending details of a capital raising.

 
Buxton Resources Ltd sees nickel-copper sulphide potential at Double Magic

2016-08-29 proactiveinvestors.com.au
Buxton Resources Ltd (ASX:BUX) has commenced induced polarisation (IP) and resistivity surveys at the Double Magic nickel-copper project in the West Kimberley region of Western Australia. The drill results from 2015 and ongoing work during 2016 has confirmed that the most attractive exploration target at Double Magic is a primary magmatic nickel-copper sulphide deposit. Buxton has chosen to proceed with an IP survey at Double Magic because primary magmatic sulphides may not be detected by electromagnetic surveys.

 
Buxton Resources Ltd enters $1.5M nickel joint venture with Independence Group

2016-08-24 proactiveinvestors.com.au
Buxton Resources Ltd (ASX:BUX) has entered into a joint venture agreement with Independence Group NL (ASX:IGO) in respect of its nickel tenements located in the Fraser Range of Western Australia. Under the terms of the agreement, Buxton has granted Independence Group the exclusive right to acquire a 90% interest in the tenements by immediately paying $1.5 million in cash. The parties have agreed that Buxton will retain the right to explore and develop iron ore on the tenements.

 
Buxton Resources Ltd to reveal joint venture agreement

2016-08-22 proactiveinvestors.com.au
Buxton Resources Ltd (ASX:BUX) has been granted a trading halt by the ASX, pending details of a joint venture agreement. The halt will remain in place until the opening of trade on Wednesday 24th August 2016, or earlier if an announcement is made to the market.

 
Director Appointment/Resignation

2016-05-13 asx.com.au

 
 
Final Director's Interest Notice

2016-05-13 asx.com.au

 
Quarterly Cashflow Report

2016-05-02 asx.com.au

 
Quarterly Activities Report

2016-05-02 asx.com.au

 
Ram Resources starts promising nickel, copper drilling in West Kimberley

2016-04-27 proactiveinvestors.com.au
Ram Resources Ltd (ASX:RMR) is focused on its portfolio of nickel and copper prospects in the Fraser Range, Western Australia.

 
Appendix 3B

2016-04-19 asx.com.au

 
Appendix 3B

2016-04-01 asx.com.au

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...